Teva Removes Over 200 Improper Patent Listings Under Pressure from FTC
December 10, 2025
December 10, 2025
WASHINGTON, Dec. 10 -- The Federal Trade Commission issued the following news release:
* * *
Teva Removes Over 200 Improper Patent Listings Under Pressure from FTC
*
After a challenge from the Federal Trade Commission, Teva Pharmaceuticals has requested that the Food and Drug Administration (FDA) remove more than 200 improper patent listings from the FDA's Orange Book. The FTC sent a series of warning letters in May 2025 to Teva and severa . . .
* * *
Teva Removes Over 200 Improper Patent Listings Under Pressure from FTC
*
After a challenge from the Federal Trade Commission, Teva Pharmaceuticals has requested that the Food and Drug Administration (FDA) remove more than 200 improper patent listings from the FDA's Orange Book. The FTC sent a series of warning letters in May 2025 to Teva and severa . . .